ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with... | May 12, 2023